RecruitingNCT05676099
TSC Biosample Repository and Natural History Database
Studying Lymphangioleiomyomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Tuberous Sclerosis Association
- Principal Investigator
- Steve Roberds, PhDTSC Alliance
- Intervention
- Phlebotomy(procedure)
- Enrollment
- 5000 enrolled
- Eligibility
- All sexes
- Timeline
- 2016 – 2050
Study locations (24)
- University of Alabama Birmingham, Birmingham, Alabama, United States
- Loma Linda University Children's Hospital, Loma Linda, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- Jack & Julia Center for TSC, Oakland Children's Hospital and Research Center, Oakland, California, United States
- The Children's Hospital, Denver, Colorado, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Chicago Comer Children's Hospital Neurogenetic Clinic, University of Chicago, Chicago, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- TSC Alliance, Silver Spring, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Minnesota Epilepsy Group, Roseville, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- New York University Medical Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05676099 on ClinicalTrials.govOther trials for Lymphangioleiomyomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06889168Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)Columbia University
- RECRUITINGPHASE4NCT07138144Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpJosé Antonio Mata Marín
- RECRUITINGNANCT07304856Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis ComplexUniversity of Milan
- ACTIVE NOT RECRUITINGPHASE2NCT06519357A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- RECRUITINGNANCT06405997The Genotype and Phenotype of LymphangioleiomyomatosisNational Taiwan University Hospital
- RECRUITINGPHASE4NCT06907056Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoJosé Antonio Mata Marín
- ENROLLING BY INVITATIONNCT05727852Breath Analysis and Arterial Stiffness in Patients With Respiratory DiseasesI.M. Sechenov First Moscow State Medical University
- ACTIVE NOT RECRUITINGPHASE1NCT05467397Feasibility of [11C]Acetate-PET in LAM and TSCBrigham and Women's Hospital